Ian Mortimer sold $1.8M of XENE
PRESIDENT & CEO at Xenon Pharmaceuticals Inc.. 40,000 shares at an average of $44.43, traded Jan 2, 2026, filed Jan 2, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.8M at market
- +20Share of holdings soldSold 87% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.8%, 3m +27.8%, 6m +37.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-001172, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | MOption exercise Common Shares10b5-1 | +40,000 | $7.49 | $300k | 46,000 | Jan 2, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Shares10b5-1 | -37,938 | $44.40 | $1.7M | 8,062 | Jan 2, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Shares10b5-1 | -2,062 | $44.93 | $93k | 6,000 | Jan 2, 2026 |
| Jan 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 0 | Jan 2, 2026 |
Related signals
Other insiders at Xenon Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 75Notable | Xenon Pharmaceuticals Inc. | Thomas Patrick Kelly Chief Financial Officer | $560k 15,000 shares | - | |
| 86Strong | Xenon Pharmaceuticals Inc. | Ian Mortimer PRESIDENT & CEO | $1.1M 30,000 shares | +151% | |
| 32Weak | Xenon Pharmaceuticals Inc. | Christopher John Kenney Chief Medical Officer | $426k 7,068 shares | -100% | |
| 55Moderate | XENEsell Xenon Pharmaceuticals Inc. | Steven Gannon director | $641k 10,000 shares | -84% | |
| 21Weak | Xenon Pharmaceuticals Inc. | Gillian Cannon director | $63k 1,190 shares | -45% | |
| 11Weak | Xenon Pharmaceuticals Inc. | Gary Patou director | $70k 1,322 shares | -5% | |
| 8Weak | Xenon Pharmaceuticals Inc. | Andrea DiFabio Chief Legal Officer | $74k 1,342 shares | -16% | |
| 9Weak | Xenon Pharmaceuticals Inc. | Christopher John Kenney Chief Medical Officer | $78k 1,410 shares | -17% | |
| 31Weak | Xenon Pharmaceuticals Inc. | Ian Mortimer PRESIDENT & CEO | $404k 7,308 shares | -27% | |
| 16Weak | Xenon Pharmaceuticals Inc. | Andrea DiFabio Chief Legal Officer | $157k 2,607 shares | -35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.